BIRMINGHAM, Alabama (April 5, 2021) — Encompass Health Corp. has announced that April Anthony has decided to step down as CEO of its home health and hospice business effective mid-June 2021
“Throughout our more than six years working together, April has provided outstanding leadership to the home health and hospice business,” said Mark Tarr, president and CEO of Encompass Health. “Together, we have grown this segment’s revenue from approximately $400 million to $1.1 billion and substantially increased the geographical footprint of our services. We thank April for her innumerable contributions, which will have a lasting positive impact.”
Encompass Health offers both facility–based and home–based patient care through a network that includes 138 hospitals, 241 home health locations, and 82 hospice locations in 39 states and Puerto Rico.
“It’s been my honor to lead Encompass Health’s home health and hospice segment, and I am proud of what we have accomplished," Anthony said. "We have developed a premier network of nurses, therapists, social workers and home health aides across the country and have set a new industry standard for providing high-quality, cost-effective integrated care. With our culture, talented workforce and technology in place to deliver superior clinical outcomes, the division is poised for ongoing success, and now is the right time for me to step aside. I look forward to working together over the coming months to achieve a successful transition.”
“Our home health and hospice business is positioned to meet the demands of an aging population that has a strong and increasing preference for in-home care," Anthony added. "Our search process to identify a successor is underway, and we have a strong foundation in place to aid in this transition. As we continue our review of strategic alternatives for our home health and hospice business, we will maintain our focus on operational excellence.”
The Encompass Health board of director’s review of strategic alternatives for the home health and hospice business, announced on Dec. 9, 2020, remains ongoing. No timetable has been established for the completion of the strategic review, and the company does not intend to disclose further developments with respect to its strategic review process, unless and until its board approves a specific transaction or action, or otherwise concludes the strategic review.
